Crowley Wealth Management Inc. Takes Position in Moderna, Inc. (NASDAQ:MRNA)

Crowley Wealth Management Inc. bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 975 shares of the company’s stock, valued at approximately $41,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of MRNA. State Street Corp grew its position in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares during the period. Wellington Management Group LLP grew its position in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares during the period. Amundi grew its position in shares of Moderna by 79.8% during the 4th quarter. Amundi now owns 1,206,273 shares of the company’s stock valued at $52,075,000 after acquiring an additional 535,273 shares during the period. Two Sigma Advisers LP bought a new position in shares of Moderna during the 3rd quarter valued at approximately $23,825,000. Finally, Douglas Lane & Associates LLC grew its position in shares of Moderna by 62.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after acquiring an additional 298,715 shares during the period. 75.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on MRNA. UBS Group dropped their price target on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and dropped their price target for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. JPMorgan Chase & Co. dropped their price target on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a research note on Friday. Morgan Stanley dropped their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Finally, Citigroup began coverage on shares of Moderna in a research note on Thursday, March 13th. They set a “neutral” rating and a $40.00 price target on the stock. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus target price of $59.00.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $32.66 on Monday. The company’s fifty day moving average price is $34.91 and its 200-day moving average price is $45.67. The firm has a market capitalization of $12.60 billion, a price-to-earnings ratio of -3.52 and a beta of 1.86. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.